Research & Development
Mylan to acquire global marketing rights for Mapi Pharma's GA Depot
12 April 2018 -

United States-based Mylan has agreed to acquire global marketing rights for Israel-based Mapi Pharma's GA Depot, a long-acting once-monthly Glatiramer acetate product, it was reported yesterday.

Both firms will also collaborate on the development and commercialisation of GA Depot. GA Depot is a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis. The collaboration is subject to approval by the Israeli Innovation Authority.

Mapi Pharma and Mylan are in the process of preparing to submit an investigational new drug application to the United States Food and Drug Administration (FDA), as well as other global health authorities, and to commence a pivotal Phase III clinical trial to support a new drug marketing application under the 505(b)(2) regulatory pathway.



Related Headlines